Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

• Published in: Clinical cancer research 2022-01, Vol.28 (2), p.318-326
• Main Authors: Stopsack, Konrad H, Nandakumar, Subhiksha, Arora, Kanika, Nguyen, Bastien, Vasselman, Samantha E, Nweji, Barbara, McBride, Sean M, Morris, Michael J, Rathkopf, Dana E, Slovin, Susan F, Danila, Daniel C, Autio, Karen A, Scher, Howard I, Mucci, Lorelei A, Solit, David B, Gönen, Mithat, Chen, Yu, Berger, Michael F, Schultz, Nikolaus, Abida, Wassim, Kantoff, Philip W
• Format: Article
• Language: English
• Subjects: Blacks; Humans; Male; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - genetics; Risk Factors; Self Report; Whites
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-21-2577

Black men die from prostate cancer twice as often as White men, a disparity likely due to inherited genetics, modifiable cancer risk factors, and healthcare access. It is incompletely understood how and why tumor genomes differ by self-reported race and genetic ancestry. Among 2,069 men with prostate cancer (1,841 self-reported White, 63 Asian, 165 Black) with access to clinical-grade sequencing at the same cancer center, prevalence of tumor and germline alterations was assessed in cancer driver genes reported to have different alteration prevalence by race. Clinical characteristics such as prostate-specific antigen and age at diagnosis as well as cancer stage at sample procurement differed by self-reported race. However, most genomic differences persisted when adjusting for clinical characteristics. Tumors from Black men harbored fewer mutations and more alterations than those from White men. Tumors from Asian men had more mutations and more alterations than White men. Despite fewer mutations, tumors from Black men had more aneuploidy, particularly chromosome arm 8q gains, an adverse prognostic factor. Genetic ancestry was associated with similar tumor alterations as self-reported race, but also with modifiable cancer risk factors. Community-level average income was associated with chr8q gains after adjusting for race and ancestry. Tumor genomics differed by race even after accounting for clinical characteristics. Equalizing access to care may not fully eliminate such differences. Therapies for alterations more common in racial minorities are needed. Tumor genomic differences should not be assumed to be entirely due to germline genetics.